These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31350321)

  • 101. Diffusion-weighted MRI,
    Kitajima K; Yamamoto S; Kawanaka Y; Nakanishi Y; Yamada Y; Go S; Kanematsu A; Kaida H; Yamakado K
    Hell J Nucl Med; 2020; 23(1):34-39. PubMed ID: 32222730
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
    Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
    Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance.
    Salguero J; Gómez-Gómez E; Valero-Rosa J; Carrasco-Valiente J; Mesa J; Martin C; Campos-Hernández JP; Rubio JM; López D; Requena MJ
    Korean J Radiol; 2021 Apr; 22(4):559-567. PubMed ID: 33289358
    [TBL] [Abstract][Full Text] [Related]  

  • 104. PI-RADSv2: How we do it.
    Greer MD; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2017 Jul; 46(1):11-23. PubMed ID: 28236334
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.
    Grivas N; Lardas M; Espinós EL; Lam TB; Rouviere O; Mottet N; van den Bergh RCN;
    Eur Urol; 2022 Nov; 82(5):452-457. PubMed ID: 35985901
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
    Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
    BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.
    Giganti F; Allen C; Emberton M; Moore CM; Kasivisvanathan V;
    Eur Urol Oncol; 2020 Oct; 3(5):615-619. PubMed ID: 32646850
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men.
    Venderink W; van Luijtelaar A; van der Leest M; Barentsz JO; Jenniskens SFM; Sedelaar MJP; Hulsbergen-van de Kaa C; Overduin CG; Fütterer JJ
    BJU Int; 2019 Nov; 124(5):775-784. PubMed ID: 31237388
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
    BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
    [TBL] [Abstract][Full Text] [Related]  

  • 111. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
    Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
    Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore.
    Cheng LJ; Soon SS; Tan TW; Tan CH; Lim TSK; Tay KJ; Loke WT; Ang B; Chiong E; Ng K
    BMC Health Serv Res; 2021 Sep; 21(1):909. PubMed ID: 34479565
    [TBL] [Abstract][Full Text] [Related]  

  • 113.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 115. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
    Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
    Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer.
    Costa DN; Lotan Y; Rofsky NM; Roehrborn C; Liu A; Hornberger B; Xi Y; Francis F; Pedrosa I
    J Urol; 2016 Jan; 195(1):80-7. PubMed ID: 26192254
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    Purysko AS; Bittencourt LK; Bullen JA; Mostardeiro TR; Herts BR; Klein EA
    AJR Am J Roentgenol; 2017 Aug; 209(2):339-349. PubMed ID: 28570099
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.
    Pye H; Singh S; Norris JM; Carmona Echeverria LM; Stavrinides V; Grey A; Dinneen E; Pilavachi E; Clemente J; Heavey S; Stopka-Farooqui U; Simpson BS; Bonet-Carne E; Patel D; Barker P; Burling K; Stevens N; Ng T; Panagiotaki E; Hawkes D; Alexander DC; Rodriguez-Justo M; Haider A; Freeman A; Kirkham A; Atkinson D; Allen C; Shaw G; Beeston T; Brizmohun Appayya M; Latifoltojar A; Johnston EW; Emberton M; Moore CM; Ahmed HU; Punwani S; Whitaker HC
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924255
    [No Abstract]   [Full Text] [Related]  

  • 119. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Chu CE; Lonergan PE; Washington SL; Cowan JE; Shinohara K; Westphalen AC; Carroll PR; Cooperberg MR
    Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.